18F-FAPI-74 in Tuberculosis Patients

Inclusion Criteria

• •Greater than or equal to 18 years of age
• •Culture confirmation of M. tuberculosis, or sputum positive by molecular testing (GeneXpert).
• •Imaging evidence of suspected M. tuberculosis disease involving lung, and possible additional other sites of involvement. Modalities can include any imaging modality such as chest x-ray, CT, ultrasound, MRI, 18F-fluorodeoxyglucose (18F-FDG) PET/CT, bone scan.
• •TB treatment initiation within 6-weeks by the time of the study PET/CT scan OR within 6-weeks after receiving 6-months of TB treatments. Using this approach, we will be able to assess fibrosis in TB patients at treatment initiation as well as having received TB treatments. The same patient may be re-consented for a scan at the later time-point.
• •Subject is willing to give written informed consent. Subject is willing and able to comply with the protocol for the duration of the study including undergoing scheduled visits and study procedures.
• •Screening clinical laboratory values must be within normal limits or judged not clinically significant by the investigator.
• •Women of child-bearing potential (WOCBP) must have a negative serum or urine pregnancy test within 24 hours prior to the radiotracer administration.
• •Patients or their legal representatives must have the ability to read, understand and provide written informed consent for the initiation of any study related procedures.